Tailored Therapies for Cardiogenic Shock in Hypertrophic Cardiomyopathy: Navigating Emerging Strategies
Hypertrophic cardiomyopathy (HCM) is a complex and heterogeneous cardiac disorder, often complicated by cardiogenic shock, a life-threatening condition marked by severe cardiac output failure. Managing cardiogenic shock in HCM patients presents unique challenges due to the distinct pathophysiology o...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Journal of Cardiovascular Development and Disease |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2308-3425/11/12/401 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846104224138526720 |
|---|---|
| author | George E. Zakynthinos Ioannis Gialamas Vasiliki Tsolaki Panteleimon Pantelidis Athina Goliopoulou Maria Ioanna Gounaridi Ioanna Tzima Andrew Xanthopoulos Konstantinos Kalogeras Gerasimos Siasos Evangelos Oikonomou |
| author_facet | George E. Zakynthinos Ioannis Gialamas Vasiliki Tsolaki Panteleimon Pantelidis Athina Goliopoulou Maria Ioanna Gounaridi Ioanna Tzima Andrew Xanthopoulos Konstantinos Kalogeras Gerasimos Siasos Evangelos Oikonomou |
| author_sort | George E. Zakynthinos |
| collection | DOAJ |
| description | Hypertrophic cardiomyopathy (HCM) is a complex and heterogeneous cardiac disorder, often complicated by cardiogenic shock, a life-threatening condition marked by severe cardiac output failure. Managing cardiogenic shock in HCM patients presents unique challenges due to the distinct pathophysiology of the disease, which includes dynamic left ventricular outflow tract obstruction, diastolic dysfunction, and myocardial ischemia. This review discusses current and emerging therapeutic strategies tailored to address the complexities of HCM-associated cardiogenic shock and other diseases with similar pathophysiology that provoke left ventricular outflow tract obstruction. We explore the role of pharmacological interventions, including the use of vasopressors and inotropes, which are crucial in stabilizing hemodynamics but require careful selection to avoid exacerbating the outflow obstruction. Additionally, the review highlights advancements in mechanical circulatory support devices such as extracorporeal membrane oxygenation (ECMO) and left ventricular assist devices (LVADs), which have become vital in the acute management of cardiogenic shock. These devices provide temporary support and bridge patients to recovery, definitive therapy, or heart transplantation, which remains a critical option for those with end-stage disease. Furthermore, the review delves into the latest research and clinical trials that are refining these therapeutic approaches, ensuring they are optimized for HCM patients. The impact of these treatments on patient outcomes, including survival rates and quality of life, is also critically assessed. In conclusion, this review underscores the importance of a tailored therapeutic approach in managing cardiogenic shock in HCM patients, integrating pharmacological and mechanical support strategies to improve outcomes in this high-risk population. |
| format | Article |
| id | doaj-art-8b768e664a1348e985655243052a76b6 |
| institution | Kabale University |
| issn | 2308-3425 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Cardiovascular Development and Disease |
| spelling | doaj-art-8b768e664a1348e985655243052a76b62024-12-27T14:31:51ZengMDPI AGJournal of Cardiovascular Development and Disease2308-34252024-12-01111240110.3390/jcdd11120401Tailored Therapies for Cardiogenic Shock in Hypertrophic Cardiomyopathy: Navigating Emerging StrategiesGeorge E. Zakynthinos0Ioannis Gialamas1Vasiliki Tsolaki2Panteleimon Pantelidis3Athina Goliopoulou4Maria Ioanna Gounaridi5Ioanna Tzima6Andrew Xanthopoulos7Konstantinos Kalogeras8Gerasimos Siasos9Evangelos Oikonomou103rd Department of Cardiology, “Sotiria” Chest Diseases Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece3rd Department of Cardiology, “Sotiria” Chest Diseases Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceCritical Care Department, University Hospital of Larissa, Faculty of Medicine, University of Thessaly, 41335 Larissa, Greece3rd Department of Cardiology, “Sotiria” Chest Diseases Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece3rd Department of Cardiology, “Sotiria” Chest Diseases Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece3rd Department of Cardiology, “Sotiria” Chest Diseases Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece3rd Department of Cardiology, “Sotiria” Chest Diseases Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceDepartment of Cardiology, University Hospital of Larissa, Faculty of Medicine, University of Thessaly, 41110 Larissa, Greece3rd Department of Cardiology, “Sotiria” Chest Diseases Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece3rd Department of Cardiology, “Sotiria” Chest Diseases Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece3rd Department of Cardiology, “Sotiria” Chest Diseases Hospital, Medical School, National and Kapodistrian University of Athens, 11527 Athens, GreeceHypertrophic cardiomyopathy (HCM) is a complex and heterogeneous cardiac disorder, often complicated by cardiogenic shock, a life-threatening condition marked by severe cardiac output failure. Managing cardiogenic shock in HCM patients presents unique challenges due to the distinct pathophysiology of the disease, which includes dynamic left ventricular outflow tract obstruction, diastolic dysfunction, and myocardial ischemia. This review discusses current and emerging therapeutic strategies tailored to address the complexities of HCM-associated cardiogenic shock and other diseases with similar pathophysiology that provoke left ventricular outflow tract obstruction. We explore the role of pharmacological interventions, including the use of vasopressors and inotropes, which are crucial in stabilizing hemodynamics but require careful selection to avoid exacerbating the outflow obstruction. Additionally, the review highlights advancements in mechanical circulatory support devices such as extracorporeal membrane oxygenation (ECMO) and left ventricular assist devices (LVADs), which have become vital in the acute management of cardiogenic shock. These devices provide temporary support and bridge patients to recovery, definitive therapy, or heart transplantation, which remains a critical option for those with end-stage disease. Furthermore, the review delves into the latest research and clinical trials that are refining these therapeutic approaches, ensuring they are optimized for HCM patients. The impact of these treatments on patient outcomes, including survival rates and quality of life, is also critically assessed. In conclusion, this review underscores the importance of a tailored therapeutic approach in managing cardiogenic shock in HCM patients, integrating pharmacological and mechanical support strategies to improve outcomes in this high-risk population.https://www.mdpi.com/2308-3425/11/12/401hypertrophic cardiomyopathycardiogenic shockmechanical circulatory supportleft ventricular outflow tract obstructionbeta-blockersextracorporeal membrane oxygenation |
| spellingShingle | George E. Zakynthinos Ioannis Gialamas Vasiliki Tsolaki Panteleimon Pantelidis Athina Goliopoulou Maria Ioanna Gounaridi Ioanna Tzima Andrew Xanthopoulos Konstantinos Kalogeras Gerasimos Siasos Evangelos Oikonomou Tailored Therapies for Cardiogenic Shock in Hypertrophic Cardiomyopathy: Navigating Emerging Strategies Journal of Cardiovascular Development and Disease hypertrophic cardiomyopathy cardiogenic shock mechanical circulatory support left ventricular outflow tract obstruction beta-blockers extracorporeal membrane oxygenation |
| title | Tailored Therapies for Cardiogenic Shock in Hypertrophic Cardiomyopathy: Navigating Emerging Strategies |
| title_full | Tailored Therapies for Cardiogenic Shock in Hypertrophic Cardiomyopathy: Navigating Emerging Strategies |
| title_fullStr | Tailored Therapies for Cardiogenic Shock in Hypertrophic Cardiomyopathy: Navigating Emerging Strategies |
| title_full_unstemmed | Tailored Therapies for Cardiogenic Shock in Hypertrophic Cardiomyopathy: Navigating Emerging Strategies |
| title_short | Tailored Therapies for Cardiogenic Shock in Hypertrophic Cardiomyopathy: Navigating Emerging Strategies |
| title_sort | tailored therapies for cardiogenic shock in hypertrophic cardiomyopathy navigating emerging strategies |
| topic | hypertrophic cardiomyopathy cardiogenic shock mechanical circulatory support left ventricular outflow tract obstruction beta-blockers extracorporeal membrane oxygenation |
| url | https://www.mdpi.com/2308-3425/11/12/401 |
| work_keys_str_mv | AT georgeezakynthinos tailoredtherapiesforcardiogenicshockinhypertrophiccardiomyopathynavigatingemergingstrategies AT ioannisgialamas tailoredtherapiesforcardiogenicshockinhypertrophiccardiomyopathynavigatingemergingstrategies AT vasilikitsolaki tailoredtherapiesforcardiogenicshockinhypertrophiccardiomyopathynavigatingemergingstrategies AT panteleimonpantelidis tailoredtherapiesforcardiogenicshockinhypertrophiccardiomyopathynavigatingemergingstrategies AT athinagoliopoulou tailoredtherapiesforcardiogenicshockinhypertrophiccardiomyopathynavigatingemergingstrategies AT mariaioannagounaridi tailoredtherapiesforcardiogenicshockinhypertrophiccardiomyopathynavigatingemergingstrategies AT ioannatzima tailoredtherapiesforcardiogenicshockinhypertrophiccardiomyopathynavigatingemergingstrategies AT andrewxanthopoulos tailoredtherapiesforcardiogenicshockinhypertrophiccardiomyopathynavigatingemergingstrategies AT konstantinoskalogeras tailoredtherapiesforcardiogenicshockinhypertrophiccardiomyopathynavigatingemergingstrategies AT gerasimossiasos tailoredtherapiesforcardiogenicshockinhypertrophiccardiomyopathynavigatingemergingstrategies AT evangelosoikonomou tailoredtherapiesforcardiogenicshockinhypertrophiccardiomyopathynavigatingemergingstrategies |